中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

38 records (took 0.032 seconds)

    Method for providing diagnosis of cancer using seprase as a marker
    12.
    发明授权
    Method for providing diagnosis of cancer using seprase as a marker 有权
    使用seprase作为标记提供癌症诊断的方法

    公开(公告)号：US08980573B2

    公开(公告)日：2015-03-17

    申请号：US12791946

    申请日：2010-06-02

    Applicant: Wolfgang Rollinger ,  Johann Karl ,  Jarema Peter Kochan ,  Markus Roessler ,  Michael Tacke

    Inventor： Wolfgang Rollinger ,  Johann Karl ,  Jarema Peter Kochan ,  Markus Roessler ,  Michael Tacke

    IPC: C12Q1/37 ,  G01N33/574

    CPC classification number: G01N33/57423 ,  G01N33/57407 ,  G01N33/57419 ,  G01N33/57473 ,  G01N2333/96411

    Abstract: The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the human fibroblast activation protein (FAP/seprase) as a universal marker of different cancer types. Seprase aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., esophagus, head and neck cancer, stomach cancer, bile duct cancer, pancreas cancer, kidney cancer, cervix cancer, ovary cancer, breast cancer, bladder cancer, endometrium cancer or prostate cancer. Furthermore, it especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring seprase in said sample. Measurement of seprase can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.

    Abstract translation: 本发明涉及一种协助癌症评估的方法。 它公开了使用人成纤维细胞活化蛋白（FAP / seprase）作为不同癌症类型的通用标记物。 Seprase有助于评估肺或肺癌（LC）或结肠癌，例如非小细胞肺癌（NSCLC）或结肠直肠癌（CRC），但也可能是其他特定类型的癌症。 这些特定的癌症类型是例如食管，头颈癌，胃癌，胆管癌，胰腺癌，肾癌，子宫颈癌，卵巢癌，乳腺癌，膀胱癌，子宫内膜癌或前列腺癌。 此外，它特别涉及通过测量所述样品中的seprase从源自个体的液体样品中评估癌症的方法。 seprase的测量可以例如用于癌症的早期检测或用于进行手术的患者的监视。

    ARMET as a marker for cancer
    20.
    发明授权
    ARMET as a marker for cancer 有权
    ARMET作为癌症的标志物

    公开(公告)号：US08741587B2

    公开(公告)日：2014-06-03

    申请号：US13103123

    申请日：2011-05-09

    Applicant: Markus Roessler ,  Johann Karl ,  Julia Riedlinger ,  Ingo Lindner ,  Michael Tacke

    Inventor： Markus Roessler ,  Johann Karl ,  Julia Riedlinger ,  Ingo Lindner ,  Michael Tacke

    IPC: G01N33/574

    CPC classification number: G01N33/57488 ,  G01N33/57423 ,  G01N33/57484 ,  G01N2333/475 ,  G01N2800/52

    Abstract: Disclosed is a method aiding in the assessment of cancer. More specifically disclosed is the use of the arginine-rich metastasized in early tumors protein (=ARMET) as a universal marker of different cancer types. ARMET aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., breast, ovary, cervix, head and neck, endometrium, melanoma, bladder, kidney, pancreas, prostate, esophagus, stomach or bile duct cancer. Further disclosed is a method for assessing cancer from a liquid sample, derived from an individual by measuring ARMET in the sample. Measurement of ARMET can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.

    Abstract translation: 披露了一种有助于评估癌症的方法。 更具体地公开了在早期肿瘤蛋白（= ARMET）中转移的精氨酸富集作为不同癌症类型的通用标记物的用途。 ARMET有助于评估肺或肺癌（LC）或结肠癌，例如非小细胞肺癌（NSCLC）或结肠直肠癌（CRC），但也可能是其他特定类型的癌症。 这些特定的癌症类型是例如乳腺，卵巢，子宫颈，头颈部，子宫内膜，黑素瘤，膀胱，肾，胰腺，前列腺，食管，胃或胆管癌。 进一步公开了一种通过测量样品中的ARMET从个体获得的来自液体样品的癌症的方法。 例如，可以将ARMET的测量用于癌症的早期检测或用于进行手术的患者的监视。

Patent Agency Ranking